Evidence map›Paper›PMID 32923607›Full record

ArticleScience advances2020

Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB-VCAM-1 axis.

Yue Li, Ahmad M N Alhendi, Mei-Chun Yeh, Mina Elahy, Fernando S Santiago, Nandan P Deshpande, Ben Wu, Enoch Chan, Shafqat Inam, Leonel Prado-Lourenco and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Oral Administration ofAntioxidants (Basel, Switzerland) · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 2 countries.

Yue LiVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-5304-9188
Ahmad M N AlhendiVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Mei-Chun YehVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Mina ElahyVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Fernando S SantiagoVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Nandan P DeshpandeSystems Biology Initiative, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-0324-8728
Ben WuVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Enoch ChanVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-1213-3428
Shafqat InamVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Leonel Prado-LourencoVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.
Jessica MarchandAdvanced Molecular Technologies Pty Ltd, Scoresby, VIC 3179, Australia.
Rohan D JoyceAdvanced Molecular Technologies Pty Ltd, Scoresby, VIC 3179, Australia.ORCID 0000-0002-6584-2562
Lorna E Wilkinson-WhiteSydney Analytical Core Facility, University of Sydney, NSW 2006, Australia.
Mark J RafteryBioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0001-8530-2814
Meidong ZhuNew South Wales Tissue Bank, New South Wales Organ and Tissue Donation Service, South Eastern Sydney Local Health District, Kogarah, NSW 2217, Australia.
Samuel J AdamsonGreenLight Clinical Pty. Ltd., Woolloomooloo, NSW 2011, Australia.ORCID 0000-0002-9397-0895
François BarnatIris Pharma, La Gaude 06610, France.
Karen Viaud-QuentricIris Pharma, La Gaude 06610, France.
Jim SocklerStatistical Operations and Programming, Datapharm Australia Pty. Ltd., Drummoyne, NSW 2047, Australia.
Joel P MackaySchool of Life and Environmental Sciences, University of Sydney, NSW 2006, Australia.ORCID 0000-0001-7508-8033
Andrew ChangSave Sight Institute, Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, NSW 2006, Australia.
Paul MitchellCentre for Vision Research, Department of Ophthalmology, Westmead Institute for Medical Research, Westmead Hospital, University of Sydney, Westmead, NSW 2145, Australia.
Sebastian M MarcuccioAdvanced Molecular Technologies Pty Ltd, Scoresby, VIC 3179, Australia.
Levon M KhachigianVascular Biology and Translational Research, School of Medical Sciences and UNSW Medicine, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0003-3446-0323
UNSW Sydney · AULauder Business School · ATMedical Developments International (Australia) · AUSydney Hospital · AUThe University of Sydney · AUData61 · AULa Trobe University · AUWestmead Hospital · AUWoolmark (Australia) · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular permeability and angiogenesis underpin neovascular age-related macular degeneration and diabetic retinopathy. While anti-VEGF therapies are widely used clinically, many patients do not respond optimally, or at all, and small-molecule therapies are lacking. Here, we identified a dibenzoxazepinone BT2 that inhibits endothelial cell proliferation, migration, wound repair in vitro, network formation, and angiogenesis in mice bearing Matrigel plugs. BT2 interacts with MEK1 and inhibits ERK phosphorylation and the expression of FosB/ΔFosB, VCAM-1, and many genes involved in proliferation, migration, angiogenesis, and inflammation. BT2 reduced retinal vascular leakage following rat choroidal laser trauma and rabbit intravitreal VEGF-A

Indexed as

Capillary PermeabilityVascular Cell Adhesion Molecule-1Angiogenesis InhibitorsAnimalsHumansMiceNeovascularization, PathologicProto-Oncogene Proteins c-fosRabbitsRatsVascular Endothelial Growth Factor AAngiogenesis InhibitorsFOSB protein, humanFosb protein, mouseFosb protein, ratProto-Oncogene Proteins c-fosVascular Cell Adhesion Molecule-1Vascular Endothelial Growth Factor A

Identifiers

PMID32923607
PMCPMC7450479
OpenAlexW3046155618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.